NCT06116461View on ClinicalTrials.gov

Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response

PHASE4RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 5, 2022

Primary Completion Date

October 1, 2024

Study Completion Date

January 31, 2025

Conditions
Melanoma
Interventions
DRUG

Nivolumab

Participants receive three reduced doses of 240 mg every four weeks

Trial Locations (1)

Unknown

RECRUITING

Erasmus MC, Rotterdam

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT06116461 - Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response | Biotech Hunter | Biotech Hunter